Access
To read this article in full you may need to log in, make a payment or gain access through a site license (see right).
Perspective
Nature Reviews Drug Discovery 4, 815–818 (1 October 2005) | doi:10.1038/nrd1849
Anticipating change in drug development: the emerging era of translational medicine and therapeutics
Abstract
Despite the large investments made in drug discovery in the past decade, there is still a dearth of new drugs. This highlights the persistence of a model of drug development that has not adapted to changes in science, public perception of drug companies or the marketplace. A high profit margin in the United States has shielded drug development from the usual economic pressures that would ordinarily drive reform. The strategy of merger, pursued by many companies to compensate for the failure to develop new drugs, has, in most cases, compounded the problem, imposing geographic and cultural segregation on an already inefficient process.
To read this article in full you may need to log in, make a payment or gain access through a site license (see right).
